15 October 2017 in I.P. Pavlov Russian Medical Biological Herald
There exists an interest in studying polymorphism of nitric oxide synthase genes in patients with bronchial asthma and essential hypertension. Aim: to study clinical and pathogenetic significance of polymorphism of nitric oxide synthase genes (NOS1 84G/A and NOS3 786C/T) in formation of comorbid pathology of bronchial asthma and essential hypertension. Materials and methods: in the study 71 patients participated who were treated for bronchial asthma or essential hypertension. The main group consisted of 24 patients with comorbid pathology of bronchial asthma and essential hypertension. The group of patients with isolated bronchial asthma included 23 individuals. The group of patients with isolated essential hypertension included 24 individuals. In all patients polymorphism of nitric oxide synthase genes NOS1 84G/A and NOS3 786C/T was determined. Results: the studied groups did not differ in distribution of the genotypes (χ2=2.13, p=0.712) of NOS1 84G/A polymorphism. The studied groups reliably differed in distribution of alleles (χ2=10.55, p=0.005) and of separate genotypes (χ2=10.49, p=0.03) of NOS3 786C/T polymorphism which evidences the relationship between the given polymorphism and development of bronchial asthma and essential hypertension. In patients with comorbid pathology of bronchial asthma and essential hypertension the frequency of occurrence of T-allele is higher and that of C-allele is lower (χ2=4.24, p=0.04) than in patients with isolated bronchial asthma. T-allele of NOS3 786C/T polymorphism 2.4 times increases the probability for comorbid pathology of bronchial asthma and essential hypertension in comparison with isolated bronchial asthma (OR=2.40, 95% CI: 1.04-5.56). Conclusion: evaluation of NOS3 786C/T polymorphism can be used for identification of patients with bronchial asthma with a high risk for development of essential hypertension.
31 March 2017 in I.P. Pavlov Russian Medical Biological Herald
The article presents the results of a study of bone mineral density and fracture risk assessment using FRAX tool in 179 citizens of the Ryazan region. According to the results of densitometry distal forearm in 20% of cases revealed osteopenia, and 10% - osteoporosis. The fracture risk, calculated by FRAX tool, correlates with the results of densitometry, which suggests the possibility of using FRAX for the diagnostics of osteoporosis.
6 October 2021 in I.P. Pavlov Russian Medical Biological Herald
The clinical picture and long-term prognosis of chronic obstructive pulmonary disease (COPD) largely depend on comorbid conditions, thereby prompting a relevant search for predictive and preventive methods in the pathogenesis of the disease. Cardiovascular diseases are highly prevalent among patients with COPD. Cardiovascular risks in patients with COPD are associated with changes in the activity of vasoactive mediators, with nitric oxide (NO) being the most important. The important role of nitric oxide in the body prompts it being studied as a biomarker of many diseases; however, its short half-life and rapid clearance prevent its direct assessment in the blood. In the body, nitric oxide is formed from L-arginine with the help of enzymes of NO-synthase group. NO oxide synthesis depends on the concentration of L-arginine, arginase and asymmetric dimethylarginine (inhibitory effect on NO-synthase). The presented literature review highlights modern views on the importance of nitric oxide and regulators of its synthesis in the pathogenesis of chronic obstructive pulmonary disease. It also indicates their role in the formation of comorbid conditions, and highlights processes of NO formation in the body. CONCLUSION: The components of the nitric oxide system (nitric oxide metabolites, L-arginine, arginase, dimethylarginine dimethylaminohydrolase, asymmetric and symmetric dimethylarginine) can be considered as potential biomarkers of COPD, especially in conditions of cardiovascular comorbidity. Further studies on the nitric oxide system are recommended for assessing the prognosis of the course of diseases and the effectiveness of the current therapy.
1 January 2018 in Bulletin of Russian State Medical University
2 January 2022 in Bulletin of Siberian Medicine
Background. Community-acquired pneumonia (CAP) remains one of the most common infectious diseases, occupying an important place in the structure of mortality worldwide.Aim. To evaluate the effectiveness of antimicrobial therapy for community-acquired pneumonia in hospitalized patients in real clinical practice.Materials and methods. A retrospective, observational study was conducted, which included 236 patients hospitalized for community-acquired pneumonia at the Regional Clinical Hospital in Ryazan in 2019. Based on these case histories, an analysis of the effectiveness of the initial empiric antimicrobial therapy was performed.Results. The initial empiric antimicrobial therapy in 73% of cases included administration of ceftriaxone, in 45% of cases – levofloxacin, in 14% of cases – azithromycin. It was found that initial antimicrobial therapy was effective in 58% of patients who did not require replacement for the antibiotic. A need for a change in the treatment regimen was significantly associated with an increase in the length of hospitalization (p < 0.001), heart rate upon admission (p = 0.032), myelocyte count in the complete blood count (p < 0.001), and urea and blood creatinine levels (p = 0.004 and p = 0.044, respectively). The selected antimicrobial therapy regimen was significantly associated with the expected treatment effectiveness (p = 0.039). The choice of levofloxacin in monotherapy or in combination with ceftriaxone was accompanied by a decrease in the relative risk of replacing the antimicrobial, compared with other treatment regimens (odds ratio (OR) = 0.86 (95% confidence interval (CI): 0.55–1.34) and OR = 0.57 (95% CI: 0.37–0.87), respectively).Conclusion. Empiric antimicrobial therapy for community-acquired pneumonia in real clinical practice complies with current recommendations, however, at the same time, its ineffectiveness persists. Respiratory fluoroquinolones are most effective in treating pneumonia in hospitalized patients.
15 August 2017 in Kazan medical journal
Aim. To evaluate the clinical and pathogenetic value of nitric oxide metabolites measurement in the blood of patients with bronchial asthma and essential hypertension. Methods. The study included 91 patients. Three groups were identified: patients with bronchial asthma (30 patients, group 1), patients with bronchial asthma in combination with essential hypertension (31 patients, group 2), and patients with essential hypertension (30 patients, group 3). Measurement of the level of total nitric oxide metabolites in patients’ blood was performed with the use of spectrophotometric method in light spectrum based on Griess reaction. Results. The median level of nitric oxide metabolites had the highest value in the blood of patients with bronchial asthma and accounted for 75.6 [70.4; 80.8] umol/L. Level of nitric oxide metabolites in the blood of patients with bronchial asthma in combination with essential hypertension and patients with essential hypertension was lower, accounting for 72.4 [66.2; 81.2] and 60.0 [54.6; 62.7] umol/L respectively (p